Clinical Trials
2 trialsNCT05301010 2023-02-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT05301530 2022-03-29
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 1 Completed